Antiplatelet agents for the treatment and prevention of atherothrombosis.
The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.
Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. carlo.patrono@rm.unicatt.it
Carlo
C
Patrono
Felicita
F
Andreotti
Harald
H
Arnesen
Lina
L
Badimon
Colin
C
Baigent
Jean-Philippe
JP
Collet
Raffaele
R
De Caterina
Dietrich
D
Gulba
Kurt
K
Huber
Steen
S
Husted
Steen Dalby
SD
Kristensen
João
J
Morais
Franz-Josef
FJ
Neumann
Lars Hvilsted
LH
Rasmussen
Agneta
A
Siegbahn
Philippe-Gabriel
PG
Steg
Robert F
RF
Storey
Frans
F
Van de Werf
Freek
F
Verheugt
D003324:Coronary Artery Disease / Q000097:blood / Q000517:prevention & control*; D003328:Coronary Thrombosis / Q000097:blood / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012307:Risk Factors
D010975:Platelet Aggregation Inhibitors